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Abstract
The cells’ ability to proliferate in response to growth factor
stimulation is significantly altered during cancer progression.
To investigate the mechanisms underlying these alterations
in prostate cancer, the role and expression of B1A integrin
and type 1 insulin-like growth factor receptor (IGF-IR), known
to contribute to cell proliferation and transformation, were
analyzed. Using small interfering RNA oligonucleotides to
down-regulate B1A, we show that B1A expression is required
for IGF-IR–mediated prostate cancer cell proliferation and
anchorage-independent growth. In vivo , using age-matched
transgenic adenocarcinoma of mouse prostate (TRAMP) mice
at different stages of prostate cancer [prostatic intraepithelial
neoplasia, PIN; well-differentiated adenocarcinoma, WD; and
poorly differentiated adenocarcinoma, PD], the expression of
B1A and of IGF-IR was studied. B1A and IGF-IR expression levels
were concurrently up-regulated in high PIN and WD, whereas
their expression did not correlate in late-stage PD. In contrast
to the up-regulated expression of B1A, the levels of B1C, a B1
cytoplasmic variant that inhibits cell proliferation, were
down-regulated in all stages of prostate cancer. A similar
expression pattern was observed for a B1C downstream effector,
Grb2-associated binder-1 (Gab1) which is known to inhibit
IGF-IR phosphorylation. To analyze in vitro the mechanistic
implications of B1A, B1C, and Gab1 deregulation in prostate
cancer, we investigated whether expression of either B1 variant
in B1-null cells affected IGF-IR localization. We found that
IGF-IR and B1A were colocalized in highly specialized integrin
signaling compartments, designated focal contacts. However,
in the presence of B1C, IGF-IR remained diffuse on the cell
surface and did not localize to focal contacts. The findings that
B1 integrins and IGF-IR are concurrently deregulated and that
expression of B1 integrins is necessary to achieve appropriate
IGF-IR intracellular distribution point to the important role
that the cross-talk between these receptors may have during
prostate cancer progression and will be helpful in formulating
new therapeutic strategies. (Cancer Res 2005; 65(15): 6692-700)
Introduction
Prostate cancer remains a significant health issue for aging men
and is the second leading cause of cancer death among American
men (1). Whereas substantial advances have been made in the
diagnosis and treatment of prostate cancer, the underlying causes
of this disease remain to be fully investigated. The development of
prostate cancer proceeds through a series of defined stages,
including preinvasive disease (prostatic intraepithelial neoplasia,
PIN), invasive cancer, and androgen-dependent or androgen-
independent metastases (2, 3).
The ability of neoplastic prostate cells to grow and invade is
mediated by interactions with the surrounding cells and extracel-
lular matrix–mediated by integrins (4). Integrins are crucial
regulators of differentiation, growth, survival, migration, and
invasion (5, 6). In prostate cancer, tumor cells have a markedly
different surrounding matrix than normal cells; thus, changes in
the integrin profile may be functionally relevant and contribute to
cancer progression (7, 8). A number of studies have reported
changes in integrin expression as prostate cancer progresses to an
advanced stage (7, 9, 10).
Integrins are heterodimers consisting of an a and h subunit (6).
The cytoplasmic domain of the h1 subunit, in its canonical form
(h1A), is highly conserved and is a positive regulator of cell
proliferation, development, migration, and integrin localization
(11, 12). The h1C integrin is an alternatively spliced variant of the h1
subfamily that contains a unique sequence in its cytoplasmic
domain (12). Previous studies have shown that either full-length
h1C or its cytoplasmic domain inhibits prostate cancer cell
proliferation (12). h1C is expressed in the nonproliferative,
differentiated epithelium and is selectively down-regulated in
prostatic adenocarcinoma (13–16).
Several reports in the literature suggest that there are physical
and functional interactions between integrins and components of
growth factor signaling pathways, including insulin-like growth
factor (IGF) or its downstream signaling proteins (17). However,
the role of these interactions between type 1 IGF receptor (IGF-IR)
and integrins in regulating the progression of prostate cancer is
still not clear. The IGF axis is an important modulator of growth
and development, and changes in this axis may have important
implications in malignant growth (18, 19). The IGF and its receptor
(IGF-IR) are found in human prostate stroma and epithelial cells
(20). There is, however, no consensus regarding the relative levels of
IGF-IR expression in benign and malignant prostate epithelium
and the role of IGFs in metastases. In 1996, Tennant et al. reported
that IGF-IR expression is significantly lowered at the protein and
RNA level in malignant versus benign prostate epithelium (21).
Similarly, Chott et al. reported that IGF-IR is expressed in luminal
and basal epithelium in nonneoplastic prostate but is lost in meta-
static androgen-independent prostate cancer (22). However, Kaplan
et al. did fail to show a significant increase in IGF-IR mRNA during
primary prostate tumor progression in transgenic adenocarcinoma
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of mouse prostate (TRAMP) mice, indicating the possibility
of posttranscriptional regulation of IGF-IR but showed reduced
levels of IGF-IR mRNA in metastatic lesions and in androgen-
independent disease (23). Subsequently, Nickerson et al. reported
that progression to androgen independence is associated with
increased expression of IGF-I and IGF-IR as well as increased
tyrosine phosphorylation of IGF-IR (24). Finally, in 2002, another
study has shown that IGF-IR was significantly up-regulated at the
protein and mRNA level in primary prostate cancer compared with
benign prostatic epithelium (25).
Most signaling pathways stimulated by receptor tyrosine kinases
use scaffolding adaptors like insulin receptor substrate (IRS) or
Gab known to be involved in IGF signaling axis (26, 27). Upon the
addition of growth factors, Grb2-associated binder (Gab1) becomes
tyrosine phosphorylated and recruits Src homology-2 domain-
containing tyrosine phosphatase 2 (Shp2; ref. 28). In our previous
study, we have shown that the Gab1/Shp2 complex is recruited to
the cell surface by integrins. Upon recruitment to cell surface,
Gab1/Shp2 complex causes IGF-IR dephosphorylation and causes
change in cell adhesion to laminin in response to IGF-I (29).
Previous studies have shown that overexpression of Gab1 increases
growth factor responsiveness and tumorigenicity in NIH3T3 cells
(26). A recent study has shown that overexpression of Gab1 lacking
the pleckstrin homology domain enhances (by 3-fold), whereas
wild-type Gab1 inhibits, epidermal growth factor–induced soft agar
colony formation of preneoplastic Syrian hamster cells (30).
However, studies carried out to investigate whether changes in
expression levels of Gab1 occur during cancer progression have not
been done.
In the present study, we show that IGF-IR–mediated prostate
cancer cell proliferation and anchorage-independent growth is
inhibited by h1A down-regulation. Our study highlights a role for
the h1A integrin as modulator of IGF-IR–mediated functions in
prostate cancer.
Materials and Methods
Antibodies. The following mouse monoclonal antibodies (mAb) were
used: to all human or mouse h1 integrins, Clone-18 (BD Bioscience, San
Jose, CA); to human h1 integrin (K-20; Immunotech, Marseille, France); to
phosphatidylinositol 3-kinase (PI3-K; p85; BD Bioscience); mouse IgM
specific to h1C integrin, 7D5/BF10 (31); to vinculin (Chemicon, Temecula,
CA). The following rabbit polyclonal antibodies were used: to all h1
integrins (M-106; Santa Cruz Biotechnology, Santa Cruz, CA); to Akt (Cell
Signaling, Beverly, MA); to extracellular signal-regulated kinase-2 (ERK-2,
Santa Cruz Biotechnology); to cytoplasmic domain of h1A integrin (kindly
provided by Dr. E. Ruoslahti, Cancer Research Center, The Burnham
Institute, La Jolla, CA); antibody to IGF-IR (Santa Cruz Biotechnology); to
h5 integrin (Chemicon); to h1C integrin (13); to Gab1 (Upstate
Biotechnology, Lake Placid, NY). Normal mouse IgM (ni-Ab) and normal
rabbit IgG (rIgG) were from Calbiochem (La Jolla, CA).
Transgenic mice. TRAMP mice on a pure C57BL/6 background were
bred in the colony at the University of Alabama at Birmingham School of
Medicine. Transgenic females were bred with nontransgenic littermates
(NT) males because transgenic males tend to develop prostate tumors. All
mice were maintained in a climate-controlled environment with a 12-hour
light/12-hour dark cycle and diet and water supplied ad libitum . Breeders
were fed standard pellet mouse feed (Harlan Teklad 7012, Madison, WI).
Following weaning at 3 to 4 weeks of age, the gender of offspring was
determined, males were separated from females, and a tail biopsy
was collected from each mouse. Tail DNA, isolated by standard procedures,
was used for determination of transgene incorporation by PCR as described
previously (32–34). All TRAMP mice develop premalignant changes
resembling human PIN, which ultimately progress to poorly differentiated
(PD) prostatic adenocarcinomas that metastasize to distant sites, primarily
the lymph nodes, bones, and lungs (33). The present study focused on PD
(grade 6) as an example of advanced prostate cancer, WD (grade 4) as an
example of an early-stage of adenocarcinoma, prostates grade 3 as an
example of PIN, and normal prostate (grade 1) from age-matched NT
littermates.
Animal care and treatments were conducted in accordance with
established guidelines and protocols approved by the University of Alabama
Animal Care Committee.
Preparation and analysis of tissues. At necropsy, the urogenital tract,
consisting of the prostate, the seminal vesicles, and the emptied bladder,
was weighed. A fragment of the DLP, as well as periaortic lymph nodes, were
rapidly frozen in liquid nitrogen and stored at 80jC, until further
processed. The rest of the DLP was fixed in an acid alcohol solution
containing 96% ethanol, 1% glacial acetic acid, and 3% distilled water, as
described (35). Lymph nodes were fixed in 10% neutral buffered formalin
phosphate. The fixed tissues were then embedded in paraffin and 4- to 5-Am
sections were mounted on Colorfrost/Plus microscope slides (Fisher
Scientific, Pittsburgh, PA). Sections were stained with H&E (lymph nodes)
or with Gomori trichrome staining (DLP). DLP sections were evaluated
blindly and scored using established criteria (32, 34) as normal prostate
(score 1), low PIN (score 2), high PIN (score 3), well-differentiated (WD,
score 4), moderately differentiated (MD, score 5), or poorly differentiated
(PD, score 6). Prostate sections from each mouse were evaluated blindly by
Dr. Isam A. Eltoum, a certified Pathologist (Department of Pathology,
University of Alabama at Birmingham, Birmingham, Al; refs. 32, 34). Tumors
showing grade 2 to 5 were heterogeneous and the pathologist graded them
depending on the type of tissue that is most prevalent. The MMHCC
Pathology Committee has published very elaborate guidelines in Cancer
Research (36). Dr. Isam A. Eltoum, the pathologist who has examined these
sections has followed those guidelines during his assessments of the tumor
grade.
Data analysis. Analysis of the expression levels of IGF-IR and h1 integrin
was done using SigmaStat, version 3.0 (SysStat, Inc., Evanston, IL). When the
effect of one variable was examined, one-way ANOVA was done if data in
multiple groups were normally distributed with equal variance. The
Kruskall-Wallis one-way ANOVA on ranks was used if three or more groups
were compared and the data were not normally distributed with equal
variance. If the latter two tests indicated that the groups were significantly
different, a Tukey or Dunn test was carried out, respectively, to determine
which of the groups were significantly different from the others. P values for
the appropriate tests are given with the results.
Prostate tissue lysis. TRAMP mice were maintained as described
above until they were 28 weeks of age. DLPs were collected at necropsy. In
this study, we used frozen prostate samples from TRAMP graded 3, 4, and
6 as well as prostate from age-matched NT. Tumor specimens were
extracted as follows: specimens were homogenized on ice in a Dounce
homogenizer in 100 mmol/L Tris-HCl (pH 7.4), 150 mmol/L NaCl,
0.1% Triton X-100, 1 mmol/L benzamidine, 10 Ag/mL soybean trypsin
inhibitor, 10 Ag/mL leupeptin, 1 mmo/L phenylmethylsulfonyl fluoride,
1 Ag/mL pepstatin A, 1 Amol/L calpain inhibitor, 1 mmol/L Na3VO4, and
1 mmol/L Na4O7P2. SDS was then added to a final concentration of 5%,
after which the extracts were boiled for 5 minutes. After boiling, samples
were centrifuged at 14,000  g for 20 minutes, and supernatant was
collected for protein determination using bicinchoninic acid protein
assay reagent (Pierce, Rockford, IL).
Immunoblot analysis. Proteins from TRAMP prostate tissue lysate
(PIN, WD, and PD) or from NT were electrophoresed using 7.5% SDS-PAGE
under reducing condition and transferred onto polyvinylidene difluoride
membranes, then probed sequentially with mAb to h1 integrins (Clone-18)
or to PI3-K or to IGF-IR-h, mouse IgM to h1C integrin (7D5/BF10; ref. 31),
normal mouse IgM, rabbit polyclonal antibody to h1C integrin or Gab1, or
to h5 integrin. Proteins were detected using enhanced chemiluminescence.
Immunofluorescence microscopy. GD25 murine cells transiently trans-
fected with human h1A or h1C integrin or GD25 cells stably transfected with
human h1A integrin using LipofectAMINE 2000 (Invitrogen, San Diego, CA)
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were cultured as described previously (37). Cells were seeded onto 10 Ag/mL
fibronectin-coated coverslips and processed for immunofluorescence
microscopy as described previously (38). The primary antibodies used were
K-20 to human h1 integrin or a mAb to vinculin or a polyclonal antibody to
IGF-IR-h. The secondary antibodies used were goat anti-rabbit IgG coupled
to FITC or goat anti-mouse IgG coupled to rhodamine (The Jackson
Laboratory, West Grove, PA). One hundred cells per experiment to study the
colocalization of IGF-IR and h1 integrins were examined and experiments
were done >10 times.
Small interfering RNA–mediated down-regulation of B1A integrin.
This study used small interfering RNA (siRNA) to target a region specific to
the h1A transcript. The siRNA was designed using conventional criteria (39)
and corresponded to nucleotides 2425 to 2443 of the coding region in
human h1A integrin. The sequence of siRNA was sense strand 5V-AUGGGAC-
ACGGGUGAAAAUTT-3V and antisense strand 5V-AUUUUCACCCGUGUCC-
CAUTT-3V. These sequences were submitted to BLAST search to ensure that
only the h1A integrin was targeted by the h1A integrin siRNA and that
control sequences were not homologous to any known genes. siRNA specific
to h1A integrin or control were synthesized by Dharmacon (Lafayette, CO).
Mouse h1A integrin also have the same last 18 nucleotides in its coding
regions as the human h1A integrin and correspond to nucleotides 2502 to
2519 of mouse h1A integrin coding region.
PC3, R, or R+ cells were cultured as described before (29). TRAMP-C2
(American Type Culture Collection, Manassas, VA) cells were grown in
DMEM, 2 mmol/L L-glutamine, 5 mg/mL bovine insulin, 10 nmol/L
dihydrotestosterone, 5% fetal bovine serum (FBS), and 5% Nu-Serum (BD
Biosciences, Bedford, MA). TRAMP-C2, R+, R, or PC3 cells were
transfected with siRNA (100 nmol/L) using oligofectamine (Invitrogen) in
serum-free medium. After a 4-hour incubation, cells were fed with complete
growth medium described above and incubated for additional 48 hours.
After incubation, cells were lysed and proteins were separated on SDS-PAGE
under reducing conditions. Proteins were immunoblotted with a mAb to h1
integrins (Clone-18) or to Akt or to ERK.
Sulforhodamine B assay. Proliferation was measured using sulforhod-
amine B (SRB) assay. PC3, R+, or TRAMP-C2 cells were transfected with
siRNA to h1A integrin or control siRNA or oligofectamine alone for 48 hours.
Cells were detached and seeded on 96-well cell culture plate (7.5  103 cells
per well) and allowed to attach for 5 hours in the presence of serum. After
attachment, cells were washed and incubated in the presence or in the
absence of IGF-I (100 ng/mL) in serum-free medium for 48 hours. After
Figure 1. h1A expression is essential for IGF-I-mediated
prostate cancer cell proliferation. PC3 (A and C ) and
TRAMP-C2 (B and D ) cells were transfected with 100
nmol/L h1A integrin siRNA, control siRNA or
oligofectamine alone (OLF ). A-B, after 48 hours, cells
were detached, lysed, and proteins were separated using
SDS-PAGE and immunoblotted with mAb to h1 integrins
(Clone-18) or antibody to Akt or antibody to ERK. C-D,
cells were plated in 96-well tissue culture plates in the
presence of 10% FBS for 5 hours. Cells were washed,
incubated for 48 hours in serum-free medium in the
presence or in the absence of IGF-I (100 ng/mL),
fixed, and stained with SRB (left). As plating control, one
plate was fixed and stained with SRB after 5 hours in the
presence of serum (right ). In (C ) and (D), the differences
in cell proliferation in the presence or in the absence of
IGF-I are statistically significant. *, P V 0.01.
Cancer Research
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incubation, cells were fixed and stained with SRB as described before (29).
As a plating control, one set of plates after 5 hours of cell attachments was
washed, fixed, and stained with SRB.
Anchorage-independent growth assay. Cell growth in soft agar was
assayed by scoring the number of colonies formed in medium (DMEM
supplemented with 10% FBS) containing 0.3% agarose, with a 0.5%
agarose medium underlay as described (40). R or R+ (2  103) or DU145
(5  103) cells were seeded on 60-mm diameter plates in triplicate in the
presence of IGF-I (100 ng/mL). Cells were fed with 1.5 mL of suspension
medium (DMEM supplemented with 10% FBS) every 3 days. The number
of colonies larger than 100 Am were counted after 14 days (R+ cells) or
after 21 days (DU145 cells). Cell viability was measured 48 hours after
siRNA transfection using trypan blue exclusion and plotted as percentage
of total viable cells.
Immunohistochemistry. Paraffin-embedded prostate tissue sections
from eight mice were baked for 2 hours at 60jC and washed thrice with
xylene to deparaffinize the slides. The sections were rehydrated using
ethanol and then distilled water. The sections were boiled in sodium citrate
using a steamer at 100jC to enhance antigen retrieval. Endogenous
peroxidase was quenched with 3% H2O2 for 5 minutes. Blocking was
achieved with 50% normal goat serum in TBS containing 0.2% bovine serum
albumin for 20 minutes at room temperature. The sections were then
incubated with primary antibodies (rabbit polyclonal antibody to h1
integrin, M-106, 0.8 Ag/mL or ni-rIgG, 0.8 Ag/mL) overnight at 4jC, followed
by biotinylated goat anti-rabbit IgG (3 Ag/mL, Vector Laboratories,
Burlingame, CA) for 30 minutes at room temperature. The sections were
incubated with streptavidin-peroxidase complex (5 Ag/mL, Vector Labora-
tories) for 30 minutes at room temperature. Each incubation step was
followed by three washes with TBS. Finally, 3,3V-diaminobenzidine
tetrahydrochloride dehydrate was used as chromogen (Sigma, St. Louis,
MO). Sections were then stained using hematoxylin for 1 minute. Tissue
sections were examined on an Olympus BX41 microscope and photo-
graphed using Olympus DP12 camera. The immunostaining of h1A integrin
was independently evaluated by four investigators, including Dr. David S.
Garlick (DVM, Pathologist, Department of Cancer Biology, University of
Massachusetts Medical School), H.L.G., M.B., and L.R.L. The expression of h1
integrin in prostate tissue sections of NT or TRAMP was evaluated and
recorded as a separate observation.
Results
B1A expression is essential for insulin-like growth factor-I–
mediated prostate cancer cell proliferation. To investigate the
role of h1A in IGF-I stimulated prostate cancer cell proliferation,
we down-regulated the expression of h1A in PC3 or TRAMP-C2
cells using siRNA specific to h1A integrin. As shown in Fig. 1A and B ,
B , transfection of h1A siRNA significantly down-regulated h1A
expression compared with control siRNA, without affecting the
expression of other molecules such as Akt (Fig. 1A), ERK (Fig. 1B),
or cell viability (data not shown). To investigate the role of h1A in
IGF-I stimulated cell proliferation, we transfected PC3 (Fig. 1C) or
TRAMP-C2 (Fig. 1D) cells with h1A siRNA or control siRNA and
measured their proliferative response in the presence or in the
absence of IGF-I. Cells transfected with h1A siRNA did not
respond to IGF-I (Fig. 1C and D, left), whereas IGF-I increased cell
proliferation when the cells were transfected with control siRNA
Figure 2. h1A is required for IGF-IR
mediated anchorage-independent growth.
A-B, R+ cells were transfected with 100
nmol/L h1A integrin siRNA, control siRNA
or oligofectamine alone (OLF ). A, after 48
hours, cells were detached, lysed and
proteins were separated using SDS-PAGE
and immunoblotted with a mAb to h1
integrins (Clone-18) or antibody to Akt.
B, cells were plated on 96-well tissue
culture plates in the presence of 10% FBS
for 5 hours. Cells were washed, incubated
for 48 hours in serum-free medium in the
presence or in the absence of IGF-I (100
ng/mL), fixed, and stained with SRB (left).
As plating control, one plate was fixed
and stained with SRB after 5 hours in the
presence of 10% FBS (right ). In (B ), the
differences in cell proliferation in the
presence or in the absence of IGF-I are
statistically significant. *, P V 0.01.
C, R or R+ cell viability after transfection
with control siRNA or h1A integrin siRNA
was measured. The number of viable cells
and of total cells was counted and the
percentages of viable cells were
calculated. D, R or R+ (2  103) cells
were suspended in 1.5-mL medium
containing 0.3% agarose and 10% FBS,
with a 0.5% agarose medium underlay in
60-mm diameter plates in the presence of
IGF-I (100 ng/mL). Cells were fed with
1.5-mL suspension medium (DMEM
supplemented with 10% FBS) every
3 days. The number of colonies larger than
100 Am were counted after 14 days.
Triplicate observations in three separate
experiments were done. Data from one
representative experiment.
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(Fig. 1C and D, left). Cells transfected with control siRNA or h1A
siRNA did attach to tissue culture plates in a comparable manner;
therefore, the effect observed was not a consequence of a
differential ability of these cells to adhere to the plate (Fig. 1C
and D, right). Based on these results, we conclude that h1A
integrin expression is essential for IGF-I-mediated prostate cancer
cell proliferation.
B1A is required for type 1 insulin-like growth factor
receptor–mediated cell anchorage-independent growth. IGF-
I binds to its receptor, IGF-IR, and stimulates tumor cell growth
and cell survival (18). Cells devoid of IGF-IR are unable to
undergo transformation, suggesting a crucial role for IGF-IR in
the establishment and maintenance of the transformed phenotype
(41). To investigate the role of h1A in IGF-IR-mediated prostate
cancer cell transformation, we used R or R+ cells. R cells are
3T3-like fibroblasts established from mouse embryos with a
targeted disruption of igf-ir gene and cannot be transformed by
SV40 T antigen, or an activated Ha-ras, or a combination of both
(42–44). R+ cells were generated by transfecting wild-type IGF-IR
in R cells (42–44). We down-regulated h1A in R+ cells using
siRNA specific to h1A integrin and measured the effect of IGF-I on
cell proliferation. We found significant down-regulation of h1A
integrin upon siRNA transfection in R+ cells (Fig. 2A). As shown
in Fig. 2B , h1A down-regulation prevented IGF-I stimulated R+ cell
proliferation (Fig. 2B, left), but it did not affect cell attachment
(Fig. 2B, right). In R cells, we observed significant cell death
(90%) after transfection with h1A siRNA as compared with R+
cells, indicating a crucial role for h1A integrin in cell survival in
the absence of IGF-IR (Fig. 2C). An analysis of the effect of h1A
integrin down-regulation on the cells’ ability to grow in
anchorage-independent manner shows that R+ cells formed
colonies in soft agar when transfected with control siRNA, but
their ability to grow in soft agar was completely inhibited by h1A
down-regulation (Fig. 2D). R cells did not form colonies in soft
agar (Fig. 2D) confirming a previous published observation that
IGF-IR is required for anchorage-independent growth (40). Similar
results were obtained in human prostate cancer cells, DU145,
whose viability was not affected by h1A integrin down-regulation,
although a complete inhibition of anchorage-independent growth
was achieved (data not shown). These results show that h1A
integrin expression plays a crucial role in IGF-IR-mediated cell
transformation.
B1A and type 1 insulin-like growth factor receptor expres-
sion is up-regulated in prostatic intraepithelial neoplasia
and well-differentiated prostate carcinoma. Because we have
shown that the h1A integrin regulates IGF-IR-mediated transfor-
mation (29), we investigated whether the expression levels of h1A
and IGF-IR correlate during prostate cancer progression in vivo .
We studied the expression profile of the h1A integrin and IGF-IR
in prostate tissues from TRAMP mice or from NT. We have
analyzed five prostates showing tumor grade 3, five prostates
showing tumor grade 4, and four prostates showing tumor grade
6. As shown in Fig. 3A-B , we found a significant increased
expression of IGF-IR and h1A integrin in all prostate tissues
showing grades 3 and 4 compared with prostates from NT mice
(P < 0.011). The concurrent up-regulation of h1A and IGF-IR in
the early stages of neoplastic transformation in TRAMP mice is
consistent with our model that h1A and IGF-IR form a functional
complex. In PD tumors, however, the expression of h1A was
significantly decreased relative to WD tissues, whereas levels of
IGF-IR were comparable with WD tissues, suggesting that
enhanced expression of h1A is not required to maintain the
proliferative capacity of late-stage tumor cells (Fig. 3C). Immuno-
histochemical analysis of TRAMP prostate tissue sections was
done in a qualitative manner to determine the localization of
h1 integrin. As shown in Fig. 4, we consistently found that the
Figure 3. h1A integrin and IGF-IR are upregulated in high-grade PIN and WD
TRAMP prostatic adenocarcinoma. Prostate tumor lysates from 28-week-old
TRAMP mice and their corresponding NT were separated using SDS-PAGE and
proteins were immunoblotted with mAb to h1 integrins (Clone-18), rabbit
polyclonal antibody to h1A integrin, to IGF-IR or, as loading control, mAb to PI3-K
(p85). A-B, NT, grade 3 (PIN), grade 4 (WD). C, grade 6 (PD). The results
are presented as fold increase obtained using densitometric analysis upon
normalization. Two sets of prostate tissues in two separate gels.
Cancer Research
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h1 integrin was expressed in epithelial and stroma cells in WD
but was down-regulated in PD tissue specimens. These results
indicate that a concurrent expression of IGF-IR and h1 occurs in
PIN and WD but not in PD prostate cancer in TRAMP mice.
Down-regulation of B1C integrin and Gab1 expression in
prostate carcinoma. The h1C integrin is expressed in human
nonproliferative, differentiated epithelium and is selectively down-
regulated in prostatic adenocarcinoma (13–16). Similarly, we show
here using the TRAMP model of progressive prostate carcinoma
that h1C is expressed in normal mouse prostate (Fig. 5A), but its
expression is down-regulated in PIN, WD, and PD adenocarcino-
mas (Fig. 5B). Detergent lysates of PNT1A cells were used as a
positive control (Fig. 5B, lane 1). In contrast, h5 integrin expres-
sion was found in normal (NT) and TRAMP prostates at similar
levels (Fig. 5B). These data indicate that selective down-regulation
of h1C is an early event during prostate cancer progression.
In our previous study, we have shown that h1C recruits Gab1 to
the cell surface and that Gab1 mediates h1C-negative regulation of
IGF-IR signaling (29). A potential correlation of the expression of
h1C and Gab1 was investigated. We analyzed Gab1 expression in
tissue lysates from NT, and from PIN, WD and PD TRAMP
prostates using an antibody to Gab1. Consistent with the
expression profile of h1C integrin, Gab1 seems down-regulated in
all TRAMP prostate specimens of grades 3, 4, and 6 compared with
normal (NT) prostate tissue specimens (Fig. 5C). These results
indicate that expression of h1C integrin and Gab1 correlates in both
normal and neoplastic prostate tissues.
B1A integrin recruits type 1 insulin-like growth factor
receptor to focal contacts. In our previous study, we have
shown that h1A but not h1C associates with IGF-IR and that h1C
expression down-regulates IGF-IR-mediated signaling (29). To
investigate the mechanism through which h1 integrin regulates
IGF-IR signaling, we hypothesized that h1 might regulate the
localization of IGF-IR in specific cellular signaling compartments.
The experiments were done using GD25 cells that do not express
h1 integrin, stably or transiently transfected with h1A or h1C. In
h1A stable transfectants, we found that IGF-IR was localized in
focal contacts, where vinculin (Fig. 6A-C), h1A and several
signaling molecules, such as Src and focal adhesion kinase (45),
are known to be localized in spread cells. In transiently
transfected cells, h1A and IGF-IR colocalized in focal contacts
(Fig. 6D-F), whereas upon h1C expression, IGF-IR was not found
to be localized in focal contacts (Fig. 6G-I, arrow). Moreover, in
nontransfected GD25 cells, the IGF-IR was found to be diffuse and
not localized to focal contacts, suggesting that h1A integrin is
essential for the localization of IGF-IR to focal contacts (Fig. 6G-I,
arrowhead). In conclusion, these data indicate that IGF-IR
localization is controlled by specific h1 integrins.
Discussion
The novel observation of this study is that down-regulation of
the h1A integrin via siRNA oligonucleotides results in inhibition of
IGF-IR-mediated cell proliferation and anchorage-independent
growth. It is also shown that whereas h1A and IGF-IR are up-
regulated, the h1C integrin cytoplasmic variant and Gab1, a h1C
downstream effector, are down-regulated during prostate cancer
progression. Finally, h1A’s ability to modulate IGF-IR localization
in focal contact signaling compartments, is shown to be the mech-
anism through which h1A controls IGF-IR signaling.
This is the first study that uses siRNA oligonucleotides to
integrins to prove a role for the integrin/growth factor receptor
cross-talk in prostate cancer and suggests the use of siRNA to
down-regulate integrins as a novel therapeutic approach for this
disease. The results show that IGF-mitogenic and transforming
activities but neither basal proliferation nor cell viability are
prevented by siRNA to h1A integrin. Based on this observation, we
conclude that h1A expression is essential to activate IGF-IR.
It is well established that activated IGF-IR sends signals
required for growth and transformation (41). Our results indicate
that the synergistic action of IGF-IR and h1A in stimulating
mitogenic signals during initiation of carcinogenesis is required.
In conclusion, a model can be formulated in which differential
expression and function of h1 integrins in prostate cancer
modulates cell responses to IGF via IGF-IR. We suggest a
paradigm shift that changes the point of view that (a) h1 integrins
per se contribute to tumor progression (46, 47) and that (b) the
IGF-IR per se contributes to tumor progression (18). By
elucidating the players that contribute to prostate cancer
progression, future studies will provide new insights into the
current therapeutic approaches that target either integrins or
IGF-IR.
Figure 4. h1 integrin is down-regulated in
PD TRAMP prostatic adenocarcinoma.
Paraffin sections (4-5 Am) of DLP from
28-week-old TRAMP mice were stained
with H&E (A and D ), antibodies against h1
integrin (B and E) or ni-rIgG (C and F ).
A-C, grade 4 (WD); D-F, grade 6 (PD).
Magnification, 20.
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The molecular basis and the cross-talk between the h1
integrins and IGF-IR in prostate cancer progression have not
been investigated. Our previous study has unraveled a novel
mechanism mediated by h1 integrin cytoplasmic variants that
differentially regulates IGF-mediated prostate cell adhesion to a
basement membrane protein, laminin (29). The relevance of this
observation to prostate cancer, where up-regulation of the IGF-IR
has been described (24), is that h1A by limiting cancer cell
adhesion to basement membrane proteins and promoting cell
proliferation in response to IGF presumably allows the tumor
mass to expand and invade. In contrast, h1C, a cytoplasmic
variant known to be down-regulated in prostate cancer, has the
opposite effect; it completely prevents IGF-mediated cell prolif-
eration and tumor growth, and promotes cell adhesion to
laminin. Interestingly, the loss of IGF-IR in the adult prostate
seems to cause the cells to become greatly disorganized and
loose attachment to basement membrane while remaining
viable.4 Consistent with the hypothesis that h1A integrin and
IGF-IR act as a complex that promotes cell proliferation but
inhibits cell adhesion to basement membrane, in this study, h1A
and IGF-IR are found to be concurrently up-regulated in
TRAMP prostate tissues in the early stages of neoplastic
transformation, when disruption of the basement membrane
occurs.
We describe a concurrent increase in expression of both h1A
integrin and IGF-IR in PIN and WD tumors in a defined model
of prostate cancer, designated TRAMP; in contrast, PD tumors,
where h1A is down-regulated, no longer show this correlation.
As previously described for human prostate cancer (7), the
present study shows that the expression of h1 (h1A and h1C) is
altered during cancer progression in TRAMP mice. The findings
show, specifically, that h1A integrin expression is up-regulated,
whereas h1C is down-regulated during prostate tumor progres-
sion. This suggests that up-regulated expression of h1A and
IGF-IR might contribute to uncontrolled cell division during
initiation of prostate cancer; however, increased levels of both
molecules are not required in the late stages of tumor
progression. It is, thus, expected that lack of expression of
h1A will adversely affect initiation of prostate cancer growth.
This is likely to be the result because, similarly, targeted
disruption of h1 has been recently shown to prevent initiation
of mammary tumorigenesis in vivo in a transgenic mouse
model (47).
The mechanism by which the h1 integrin cytodomain
differentially modulates prostate cancer cell functions in response
to IGF and allows IGF-IR to dissect downstream signaling
pathways occurs via differential recruitment of IGF-IR down-
stream effectors to the plasma membrane. A specific association
between integrins and IGF-IR effector molecules, specifically h1A
and IRS-1, h3 integrins and IRS-1, h3 integrins and DOK1, and h1C
and Gab1/Shp2-phosphatase complex, is likely to explain many
activities attributed to IGF-IR (29, 48–50). In this study, we show
that both h1 integrins and IGF-IR are found to be colocalized in
focal contacts where a significant amount of integrin downstream
signaling is coordinated. In contrast, expression of h1C that is
known to remain diffuse on the cell surface, prevents, or is not
able to support IGF-IR localization in focal contacts. The
relevance of these findings to prostate cancer is high because
both h1C and Gab1 are down-regulated in prostate cancer when
h1A is up-regulated. Presumably, in normal tissues, by preventing
IGF-IR localization to focal contacts, h1C potentiates Gab1/Shp2
signaling that in turn keeps IGF-IR in a nonphosphorylated
state. In contrast, in neoplastic tissues, an appropriate localization
of IGF-IR in focal contacts mediated by h1A association with IGF-
IR maintains IRS-1 signaling active and supports tumor
progression.
In conclusion, deregulated expression of integrins and of IGF-
IR and deregulation of their cross-talk is likely to be responsible
for several alterations of cell functions and intracellular signaling
in prostate cancer. Therefore, these alterations should be
regarded as highly significant events in the search for novel
therapeutic targets in prostate cancer.
Figure 5. Down-regulation of h1C integrin and Gab1 in PIN, WD, and PD
TRAMP prostate tissues. A, PNT1A cell lysate (lane 1) or tissue extract from
normal mouse prostate (lane 2) were separated using a 7.5% SDS-PAGE and
proteins were immunoblotted with mAb to h1C integrin or nonimmune antibody
(ni-Ab). B, PNT1A cell lysate or prostate tumor lysates from 28-week-old
TRAMP mice and their corresponding NT were separated using SDS-PAGE and
proteins were immunoblotted with rabbit polyclonal antibody to h1C integrin or
h5 integrin. C, PNT1A cell lysate or prostate tumor lysates from 28-week-old
TRAMP mice and their corresponding NT were separated using SDS-PAGE and
proteins were immunoblotted with rabbit polyclonal antibody to Gab1 or h5
integrin.
4 N.M. Greenberg, unpublished results.
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Figure 6. h1A integrin but not h1C recruits IGF-IR to focal
contacts. A-C, GD25 cells stably transfected with human h1A
integrin were stained with antibodies to IGF-IR (green ) or
vinculin (red); image-merging analysis of vinculin and IGF-IR
(yellow ). D-I, GD25 cells transiently transfected with human
h1A (D-F ) or h1C (G-I, arrow) integrin were stained with
antibodies to IGF-IR (green) or to h1 integrins (red );
image-merging analysis of h1 integrins and IGF-IR (yellow ).
G-I, nontransfected GD25 cell (arrowhead). The experiments
were repeated 10 times with similar results.
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